Patrick Van Dijck and Adam Feyaerts
A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. In a context of fungi showing increasing drug resistance, these findings may be useful in both medical and agricultural applications.
The research project, led by prof. Patrick Van Dijck, is rooted in the growing problem of antifungal drug resistance. Candida cells, for example, are quickly becoming tolerant to fluconazole, the most-used antifungal drug. Next to exploring experimental new techniques, scientists also seek to repurpose existing substances. Plant essential oils (EOs), metabolites obtained by steam distillation or cold citrus peel pressing, may offer interesting opportunities: they are made up of compounds that help protect the plant against microbial or herbivore attacks.
Identifying EOs and their compounds
In the VIB-KU Leuven Center for Microbiology, Adam Feyaerts gathered a collection of 175 different EOs, constituting a collection of over one thousand different small molecules. The aim was to identify biologically active compounds present in these complex mixtures. They therefore developed a new class of assay that allowed to identify new volatile substances with antifungal activities over a distance.
Prof. Patrick Van Dijck (VIB-KU Leuven): “We screened our whole collection of EOs for vapor-phase mediated antifungal activity against two human fungal pathogens, Candida albicans and Candida glabrata. Interestingly, we found that approximately half of the EOs and their compounds had vapour-phase-mediated activity against bothCandida species. Surprisingly, C. glabrata, the most drug-resistant species of the two was on average even more susceptible. In contrast, none of the currently used antifungals showed any vapour-phase-mediated activity.”
Numerous potential applications
This is now the first simple test to look for the vapor-phase-mediated antimicrobial activity of molecules. The same assay could also be used to test other biological activity. And although these findings still have to be confirmed in clinical trials, potential applications are numerous.
Co-author Adam Feyaerts (VIB-KU Leuven): “Our findings are for instance a starting point for the development of molecules that could also be used in vaporizers. After all, volatiles can access otherwise hard to reach areas. Think of possibilities such as maintaining hygiene in hospitals or treat patients with lung infections. There are agricultural options too, such as preventing post-harvest contamination or protecting crops against pests.”
Learn more: Plant-derived volatiles may serve as future antifungals
The Latest on: Antifungal drug resistance
via Google News
The Latest on: Antifungal drug resistance
- Humans are not prepared for a pandemic caused by fungal infectionson August 5, 2022 at 8:22 am
Changes in the environment and climate, as well as fungicide overuse in agriculture, have driven a rise in fungi capable of infecting people and evading the few drugs designed to fight them.
- F2G to push anti-fungal agent with new $70M fundingon August 4, 2022 at 1:01 am
F2G, a clinical-stage biopharma company focused on treating life-threatening rare fungal infections, has announced $70M of financing.
- Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofimon August 4, 2022 at 12:02 am
Forbion, a leading European life sciences venture capital firm, today announces the $70 million financing of F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and ...
- F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofimon August 4, 2022 at 12:00 am
F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today ...
- Researchers identify how deadly fungus develops drug resistance - studyon August 3, 2022 at 7:57 pm
However, researchers found the method by which C. neoformans develops resistance to antifungal drugs in a new peer-reviewed study published in the scientific journal Nature Microbiology on Tuesday.
- This is how highly resistant strains of fungi emergeon August 3, 2022 at 8:42 am
Antibiotic resistance is a matter of common knowledge. And the same phenomenon also occurs with drugs against pathogenic fungi. What causes it is still not very well understood.
- How highly resistant strains of fungi emergeon August 3, 2022 at 8:10 am
An international research team has deciphered the mechanism by which the fungus Cryptococcus neoformans is resistant to fungus-specific drugs. It is a yeast-like fungus that can infect humans.
- Nanoparticles Help To Combat Fungal Antimicrobial Resistanceon July 29, 2022 at 9:48 am
Antimicrobial-resistant fungal infections are concerning due to the limited availability of antifungal drugs and their related toxicity. Moreover, drug toxicity due to its nonspecific targeting may ...
- Drug resistance to fungal infections increasing: ICMR reporton July 26, 2022 at 5:00 pm
There has been a sustained increase in drug-resistant pathogens ... The report further warned against a surge in fungal infections, including those due to rare species, among hospitalised patients.
via Bing News